Human monocytic ehrlichiosis

JAMA

Volumn 292, Issue 18, 2004, Pages 2263-2270

  Stone, John H ^a,c   Dierberg, Kerry ^b   Aram, Ghazaleh ^c   Dumler, J Stephen ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXYCYCLINE; ETANERCEPT; GLUCOCORTICOID; LISINOPRIL; PLACEBO; PREDNISONE; RIFAMPICIN; ANTIINFECTIVE AGENT;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BACTERIAL TRANSMISSION; BLOOD ANALYSIS; BLOOD SMEAR; CASE REPORT; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CYTOPENIA; ECOSYSTEM; EHRLICHIA CHAFFEENSIS; EHRLICHIOSIS; FEMALE; FEVER; HEMODIALYSIS; HUMAN; LABORATORY TEST; LIVER FUNCTION; MALE; MONOCYTE; MYOCARDITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REMISSION; RISK FACTOR; SEROLOGY; THROMBOCYTOPENIA; TICK BITE; WEGENER GRANULOMATOSIS; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; DIFFERENTIAL DIAGNOSIS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED;

ANTI-BACTERIAL AGENTS; DIAGNOSIS, DIFFERENTIAL; DOXYCYCLINE; EHRLICHIA CHAFFEENSIS; EHRLICHIOSIS; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; MONOCYTES; POLYMERASE CHAIN REACTION; WEGENER GRANULOMATOSIS;

EID: 7744237378     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.18.2263     Document Type: Article

References (54)

1. The WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials. 2002;23:450-468.
2. The WGET Research Group. Etanercept in addition to standard therapy in patients with Wegener granulomatosis. N Engl J Med. In press.
3. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488-498.
4. Reinhold-Keller E, Beuge N, Latza U, et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long term outcome in 155 patients. Arthritis Rheum. 2000;43:1021-1032.
5. The WGET Research Group. Baseline data on patients in the Wegener's Granulomatosis Etanercept Trial (WGET). Arthritis Rheum. 2003;48:2299-2309.
6. Mitchell T. The pathogenesis of streptococcal infections. Nat Rev Microbiol. 2003;1:219-230.
7. Dumler JS, Barbet AF, Bekker CPJ, et al. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales; unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia, and Ehrlichia with Neorickettsia; descriptions of six new species combinations; and designation of Ehrlichia equi and "HGE agent" as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol. 2001;51:2145-2165.
8. Olano JP, Walker DH. Human ehrlichioses. Med Clin North Am. 2002;86:375-392.
9. Goldman EE, Breitschwerdt EB, Grindem CB, et al. Granulocytic ehrlichiosis in dogs from North Carolina and Virginia. J Vet Intern Med. 1998;12:61-70.
10. Wolf L, McPherson T, Harrison B, Engber B, Anderson A, Whitt P. Prevalence of Ehrlichia ewingii in Amblyomma americanum in North Carolina. J Clin Microbiol. 2000;38:2795.
11. Gardner SL, Holman RC, Krebs JW, et al. National surveillance for the human ehrlichioses in the United States, 1997-2001, and proposed methods for evaluation of data quality. Ann N Y Acad Sci. 2003;990:80-89.
12. McQuiston JH, Paddock CD, Holman RC, et al. The human ehrlichioses in the United States. Emerg Infect Dis. 1999;5:635-642.
13. Olano JP, Masters E, Hogrefe W, et al. Human monocytotropic ehrlichiosis, Missouri. Emerg Infect Dis. 2003;9:1579-1586.
14. Marshall GS, Jacobs RF, Schutze GE, et al; Tick-Borne Infections in Children Study Group. Ehrlichia chaffeensis seroprevalence among children in the southeast and south-central regions of the United States. Arch Pediatr Adolesc Med. 2002;156:166-170.
15. Paddock CD, Childs JE. Ehrlichia chaffeensis. Clin Microbiol Rev. 2003;16:37-64.
16. Childs JE, Paddock CD. The ascendancy of Amblyomma americanum as a vector of pathogens affecting humans in the United States. Annu Rev Entomol. 2003;48:307-337.
17. Varela AS, Stallknecht DE, Yabsley MJ, et al. Experimental infection of white-tailed deer (Odocoileus virginianus) with Ehrlichia chaffeensis by different inoculation routes. J Wildl Dis. 2003;39:881-886.
18. Fichtenbaum CJ, Peterson LR, Weil GJ. Ehrlichiosis presenting as a life-threatening illness with features of the toxic shock syndrome. Am J Med. 1993;95:351-357.
19. Dumler JS, Dey C, Meier F, et al. Human monocytic ehrlichiosis: a potentially severe disease in children. Arch Pediatr Adolesc Med. 2000;154:847-849.
20. Fritz CL, Kjemtrup AM, Conrad PA, et al. Seroepidemiology of emerging tickborne infectious diseases in a northern California community. J Infect Dis. 1997;175:1432-1439.
21. Fishbein DB, Dawson JE, Robinson LE. Human ehrlichiosis in the United States, 1985 to 1990. Ann Intern Med. 1994;120:736-743.
22. Dumler JS, Dawson JE, Walker DH. Human ehrlichiosis. Hum Pathol. 1993;24:391-396.
23. Walker DH, Dumler JS. Human monocytic and granulocytic ehrlichioses. Arch Pathol Lab Med. 1997;121:785-791.
24. Sehdev AE, Dumler JS. Hepatic pathology in human monocytic ehrlichiosis: Ehrlichia chaffeensis infection. Am J Clin Pathol. 2003;119:859-865.
25. Williams J, Snow R, Arciniegas J. Myocardial involvement in a patient with human ehrlichiosis. Am J Med. 1995;98:414-415.
26. Vanek NN, Kazi S, Cepero NM, et al. Human ehrlichiosis causing left ventricular dilatation and dysfunction. Clin Infect Dis. 1996;22:386-387.
27. Paddock CD, Suchard DP, Grumbach KL, et al. Fatal seronegative ehrlichiosis in a patient with HIV infection. N Engl J Med. 1993;329:1164-1167.
28. Paddock CD, Folk SM, Shore GM, et al. Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in persons coinfected with human immunodeficiency virus. Clin Infect Dis. 2001;33:1586-1594.
29. Marty AM, Dumler JS, Imes G, et al. Ehrlichiosis mimicking thrombotic thrombocytopenic purpura. Hum Pathol. 1995;26:920-925.
30. Tan HP, Dumler JS, Maley WR, et al. Human monocytic ehrlichiosis: an emerging pathogen in transplantation. Transplantation. 2001;71:1678-1680.
31. Arav-Boger R, Knepp JH, Walls JJ, et al. Human monocytic ehrlichiosis in a child with leukemia. Pediatr Infect Dis J. 2000;19:173-175.
32. Liddell AM, Sumner JW, Paddock CD, et al. Reinfection with Ehrlichia chaffeensis in a liver transplant recipient. Clin Infect Dis. 2002;34:1644-1647.
33. Sadikot R, Shaver MJ, Reeves WB. Ehrlichia chaffeensis in a renal transplant recipient. Am J Nephrol. 1999;19:674-676.
34. Talbot TR, Comer JA, Block KC. Ehrlichia chaffeensis infections among HIV-infected patients in a human monocytic ehrlichiosis-endemic area. Emerg Infect Dis. 2003;9:1123-1127.
35. Patel RG, Byrd MA. Near fatal acute respiratory distress syndrome in a patient with human ehrlichiosis. South Med J. 1999;92:333-335.
36. Smith Sehdev AE, Sehdev PS, et al. Human monocytic ehrlichiosis presenting as acute appendicitis during pregnancy. Clin Infect Dis. 2002;35:e99-e102.
37. Dunn BE, Monson TP, Dumler JS, et al. Identification of Ehrlichia chaffeensis morulae in cerebrospinal fluid mononuclear cells. J Clin Microbiol. 1992;30:2207-2210.
38. Peters TR. Severe ehrlichiosis in an adolescent taking trimethoprim-sulfamethoxazole. Pediatr Infect Dis J. 2000;19:170-172.
39. Brantley RK. Trimethoprim-sulfamethoxazole and fulminant ehrlichiosis. Pediatr Infect Dis J. 2001;20:231.
40. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor-α therapy. Arthritis Rheum. 2003;48:3013-3022.
41. Walker DH, Popov VL, Crocquet-Valdes PA, et al. Cytokine-induced, nitric oxide-dependent, intracellular antirickettsial activity of mouse endothelial cells. Lab Invest. 1997;76:129-138.
42. + Th1 cells contribute to toxic shock-like syndrome in an animal model of fatal monocytotropic ehrlichiosis. J Immunol. 2004;172:1786-1800.
43. Feng H-M, Walker DH. Mechanisms of immunity to Ehrlichia muris: a model of monocytotropic ehrlichiosis. Infect Immun. 2004;72:966-971.
44. Zhang J, McBride J, Yu X. L-selectin and E-selectin expressed on monocytes mediating Ehrlichia chaffeensis attachment onto host cells. FEMS Microbiol Lett. 2003;227:303-309.
45. Mott J, Barnewall RE, Rikihisa Y. Human granulocytic ehrlichiosis agent and Ehrlichia chaffeensis reside in different cytoplasmic compartments in HL-60 cells. Infect Immun. 1999;67:1368-1378.
46. Lin M, Rikihisa Y. Ehrlichia chaffeensis down-regulates surface Toll-like receptors 2/4, CD14 and transcription factors PU.1 and inhibits lipopolysaccharide activation of NF-κB, ERK 1/2 and p38 MAPK in host monocytes. Cell Microbiol. 2004;6:175-186.
47. Lee EH, Rikihisa Y. Anti-Ehrlichia chaffeensis antibody complexed with E. chaffeensis induces potent proinflammatory cytokine mRNA expression in human monocytes through sustained reduction of IκB-α and activation of NF-κB. Infect Immun. 1997;65:2890-2897.
48. Walker DH, Paletta CE, Cain BG. Pathogenesis of myocarditis in Rocky Mountain spotted fever. Arch Pathol Lab Med. 1980;104:171-174.
49. Marin-Garcia J. Left ventricular dysfunction in Rocky Mountain spotted fever. Clin Cardiol. 1983;6:501-506.
50. Sotomayor EA, Popov VL, Feng HM, et al. Animal model of fatal human monocytotropic ehrlichiosis. Am J Pathol. 2001;158:757-769.
51. Walker DH. Diagnosing human ehrlichiosis. ASM News. 2000;66:287-290.
52. Everett ED, Evans KA, Henry RB, McDonald G. Diagnosis using polymerase chain reaction. Ann Intern Med. 1994;120:730-735.
53. Childs JE, Sumner JW, Nicholson WL, et al. Outcome of diagnostic tests using samples from patients with culture-proven human monocytic ehrlichiosis. J Clin Microbiol. 1999;37:2997-3000.
54. Brouqui P, Raoult D. In vitro antibiotic susceptibility of the newly recognized agent of ehrlichiosis in humans, Ehrlichia chaffeensis. Antimicrob Agents Chemother. 1992;36:2799-2803.